Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.
We report a case of breakthrough invasive zygomycosis in a stem cell transplant recipient who was receiving caspofungin for treatment of a breakthrough Candida krusei fungemia that occurred during fluconazole prophylaxis. Also, patients receiving the echinocandin caspofungin remain at risk for pathogens, such as zygomycetes, that are intrinsically resistant to this agent.
Girmenia
Corrado
C
Dipartimento di Biotecnologie Cellulari ed Ematologia, University "La Sapienza," Rome 00161, Italy. girmenia@bce.uniroma1.it
Moleti
Maria Luisa
ML
Micozzi
Alessandra
A
Iori
Anna Paola
AP
Barberi
Walter
W
Foà
Robin
R
Martino
Pietro
P
D000293:Adolescent; D000741:Anemia, Aplastic / Q000628:therapy; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000145:classification / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D000077336:Caspofungin; D018890:Chemoprevention; D054714:Echinocandins; D017809:Fatal Outcome; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D016469:Fungemia / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D005658:Fungi; D006801:Humans; D055666:Lipopeptides; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D020096:Zygomycosis / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D015725:Fluconazole; D000077336:Caspofungin